Studies utilizing Gemelli’s proprietary diagnostic technologies demonstrate key clinical applications, advancements in IBS and SIBO diagnostics, and treatment support. These findings will be presented at Digestive Disease Week® 2026 (May 2-5), reflecting the increasing adoption of 3-gas breath and antibody testing.
RALEIGH, N.C.–(BUSINESS WIRE)–Gemelli Biotech announced today that its diagnostic technologies will be featured across multiple research presentations at DDW 2026, the world’s premier gathering of gastrointestinal researchers and clinicians. These studies included the use of Trio-Smart®, a diagnostic 3-gas breath test developed and distributed by Gemelli Biotech that uniquely detects hydrogen sulfide, in addition to hydrogen and methane. Comprehensive 3-gas breath testing is exclusively available through Gemelli Biotech.
The volume and diversity of DDW research reflects Gemelli’s deepening integration into the most rigorous microbiome science being conducted in the United States today. This research further validates the accuracy and utility of Gemelli’s at-home tests while showing significant cost savings that can result from a first-in-line diagnosis of small intestinal bacterial overgrowth (SIBO), post-infectious irritable bowel syndrome (PI-IBS), intestinal methanogenic overgrowth (IMO) and/or intestinal sulfide overproduction (ISO) that Gemelli tests can confidently confirm and indicate. The research being presented at this year’s DDW is actively reshaping how clinicians identify and treat some of the most common and undertreated conditions in gastroenterology.
Ritesh Agarwal, CEO of Gemelli Biotech, said, “DDW is where the most consequential GI research is presented, and having our technology at the center of so much of this year’s science speaks to a genuine shift in how the medical community is approaching chronic gut conditions. Gemelli’s proprietary diagnostics have the ability to detect hydrogen sulfide coupled with our high-precision hydrogen and methane measurement and this makes Trio-Smart® a powerful research tool. In addition, the detection of antibodies using the IBS-Smart technology allows for a better understanding of disease processes.” He continued, “It’s an honor to have Trio-Smart and IBS-Smart contribute to research that can help millions of people who suffer from gut conditions like IBS and SIBO. We look forward to expanding our work to help patients with a valid and valuable diagnostic.”
All presentations originate from the Medically Associated Science and Technology (MAST) program at Cedars-Sinai, the country’s leading institution in gut microbiome research and the scientific home of the peer-reviewed work underpinning both Trio-Smart® and IBS-Smart®.
Presented research includes:
Newest research and validation of Trio-Smart® diagnostics
1.BREATH H2S AND CH4 CORRELATE WITH THE SAME GASES IN THE DUODENUM AND GASTROINTESTINAL SYMPTOMS (5/5/2026 12:30-1:30, Poster #1699)
Newest research and validation of IBS-Smart®
1.HIGHER LEVELS OF SERUM ANTI-VINCULIN ANTIBODIES CORRELATE WITH GREATER SEVERITY OF GASTROINTESTINAL SYMPTOMS AND SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) MICROBIAL PROFILE BASED ON QUANTITATIVE SHOTGUN SEQUENCING (5/4/2026 11:45am -12:15, Poster# 767)
2.FOREIGN TRAVEL IS ASSOCIATED WITH CHANGES IN THE SMALL BOWEL MICROBIOME AND WITH ELEVATIONS IN ANTI-VINCULIN ANTIBODY LEVELS (5/5/2026 12:30-1:30, Poster #1263)
3.LEVELS OF SERUM ANTIBODIES TO CYTOLETHAL DISTENDING TOXIN B (CDTB) IN HUMAN SUBJECTS PREDICT SIBO BY SMALL BOWEL CULTURE AND AN ALTERED SMALL INTESTINAL MICROBIOME BY SHOTGUN SEQUENCING (5/5/2026 12:30-1:30, Poster #1266)
Areas that expand SIBO focus
1.QUANTITATIVE METAGENOMICS REVEALS A STRONG SIBO–TYPE 2 DIABETES LINK, WITH ELEVATED ABSOLUTE ABUNDANCES OF GRAM NEGATIVE MICROBES PERSISTING INDEPENDENT OF SIBO AND CORRELATING WITH HIGHER GLUCOSE LEVELS (5/2/2026 3:30 Oral Presentation: Room W184a)
2.PROTEOMICS OF THE SMALL BOWEL LUMEN SHOWS A DISTINCT SIGNATURE OF ANTI-MICROBIAL IMMUNE ACTIVATION AND TISSUE DAMAGE IN RESPONSE TO SIBO (5/3/2026 12:30-1:30, Poster #1292)
3.EVALUATING THE RELATIONSHIP BETWEEN THE ABSOLUTE QUANTIFICATION OF GRAM-NEGATIVE BACTERIA IN OLDER SUBJECTS WITH SMALL INTESTINAL BACTERIAL OVERGROWTH (SIBO) AND GI SYMPTOMATOLOGY (5/3/2026 12:30-1:30, Poster #1282)
4.THE ABSOLUTE ABUNDANCE OF DUODENAL METHANOGENIC ARCHAEA ACROSS BMI CATEGORIES FOLLOWS A U-SHAPED PATTERN SUGGESTING A POSSIBLE ADAPTIVE RESPONSE (5/3/2026 2-3:30, Oral Presentation Room W184a)
5.ARCHAEA ARE HIGHLY PREVALENT IN THE HUMAN SMALL INTESTINE AND THE ABSOLUTE ABUNDANCE OF METHANOBREVIBACTER IS ASSOCIATED WITH OLDER AGE AND GREATER MICROBIAL DIVERSITY (5/5/2026 12:30-1:30, Poster #1261)
6.RHEUMATOID ARTHRITIS IS ASSOCIATED WITH SMALL INTESTINAL BACTERIAL OVERGROWTH AND DISTINCT SMALL BOWEL MICROBIOME CHANGES: INTEGRATION OF ASPIRATE CULTURE WITH LARGE-SCALE DATABASE ANALYSIS (5/5/2026 12:30-1:30, Poster #1293)
7.UNVEILING THE METATRANSCRIPTOMIC PROFILE IN SUBJECTS WITH SIBO: FROM RNA TO PATHWAYS (5/5/2026 12:30-1:30, Poster #1260)
About Gemelli Biotech
Gemelli Biotech develops and distributes at-home, mail-in precision diagnostics for diseases of the gut microbiome. Our mission is to leverage leading biological discoveries related to the microbiome to provide non-invasive, easy-to-understand diagnostics. This enables clinicians to definitively detect scientifically validated biomarkers and optimally treat GI diseases including IBS, SIBO, IMO, and ISO. Our products include the Trio-Smart® breath test that measures levels of hydrogen, methane, and hydrogen sulfide; the IBS-Smart® blood test that measures validated biomarkers of IBS, anti-CdtB, and anti-vinculin, offering a positive diagnostic strategy for patients with IBS symptoms; and the Trio-Smart Malabsorption breath test that helps identify carbohydrate intolerances after lactose, fructose, or sucrose consumption. All Gemelli tests can be ordered through a healthcare provider or directly through Gemelli’s online patient platform. Visit gemellibiotech.com to learn more.
COSTA MESA, Calif., April 21, 2026 /PRNewswire/ — CerraCap Ventures investment in Nephronomics reflects strategic conviction of backing platforms that transform fragmented healthcare systems into predictive, precision-driven ecosystems.
Nephronomics is a next-generation AI-bio precision medicine company. The company is building one of the world’s most comprehensive clinical and genomic data sets focused on cardio-kidney-metabolic (CKM) disease—a rapidly emerging framework that links cardiovascular, kidney, and metabolic disorders into a unified disease model.
Nephronomics’ moat is built on data— in this AI era, data matters more than models. It has exclusive access to the largest renal dataset globally, spanning 42,000+ patients across a significant portion of U.S. dialysis clinics. This scale is difficult to replicate, positioning the company as a leader in data-driven kidney disease innovation.
Nephronomics is translating this proprietary dataset into actionable biological insight using advanced machine learning. Its platform leverages state-of-the-art capabilities—including protein modeling, variant-effect prediction, and generative design—to identify new disease subtypes, uncover causal mechanisms, and develop novel therapeutic targets.
This approach enables a shift from correlation to causation in drug discovery—accelerating the development of precision therapies that directly address disease-driving molecular pathways.
The opportunity is significant, with chronic kidney disease affecting 14% of the U.S. population and 850 million people globally. Despite over $141 billion in annual U.S. spending, kidney disease remains under-researched, creating a clear gap for precision medicine approaches. The company intends to develop a pipeline of internal therapeutic programs while also partnering with pharmaceutical companies to accelerate drug development.”For CerraCap, the investment aligns with its focus on backing AI-native infrastructure that enables systemic transformation across industries.
“This is not simply about applying AI to existing workflows,” Vikas Datt – CerraCap leadership noted. “It’s about enabling an entirely new intelligence layer for healthcare and life sciences. Nephronomics, will not only accelerate innovation in kidney disease but also demonstrate how the future of medicine will be built: on intelligent systems powered by data, driven by insight, and scaled through strategic ecosystems.”
For Nephronomics, the partnership brings more than capital—it adds strategic leverage.
CerraCap Ventures and Impact Venture Capital announced their merger to form CerraCap Impact Venture Capital (CIVC).
Based in Costa Mesa, CA, the combined firm brings together a network of corporate customers, corporate investors, and strategic acquirers, positioning CIVC as a partner for founders who need rapid commercial validation and scalable enterprise adoption.
CIVC integrates CerraCap’s Sales & Scale commercialization engine with Impact Venture Capital’s Corporate Intelligence Platform. Together, the platform gives startups accelerated access to enterprise customers, co-investors, corporate venture groups, and potential acquirers—shortening the path from early-stage innovation to revenue and ultimately to exit.
Operating at the intersection of enterprise AI, cybersecurity, digital health, national security, and advanced computing, CIVC will support founders building mission-critical technologies in sectors where commercial traction often depends on complex buyer landscapes. The firm’s combined global footprint across North America, Europe, India, and emerging markets will enable founders to access international customer and investor networks far earlier in their journey.
CIVC’s team includes:
Saurabh Ranjan, Co-Founder & Managing Partner, CerraCap Ventures
Saurabh Suri, Co-Founder & Managing Partner, CerraCap Ventures
Eric Ball, Founding General Partner, Impact Venture Capital
Jack Crawford, Founding General Partner, Impact Venture Capital